Home Cart Sign in  
Chemical Structure| 1039455-84-9 Chemical Structure| 1039455-84-9

Structure of COTI-2
CAS No.: 1039455-84-9

Chemical Structure| 1039455-84-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

COTI-2 is an orally available thiosemicarbazone and mutant p53 activator with potential antineoplastic activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of COTI-2

CAS No. :1039455-84-9
Formula : C19H22N6S
M.W : 366.48
SMILES Code : S=C(N1CCN(C2=NC=CC=C2)CC1)N/N=C3CCCC4=C\3N=CC=C4
MDL No. :MFCD28502211

Safety of COTI-2

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Description
COTI-2, distinguished as a low-toxicity anticancer agent, is an orally bioavailable third-generation p53 activator that can reactivate mutant forms of p53 and concurrently inhibit the PI3K/AKT/mTOR signaling pathway. It has been shown to trigger apoptosis across various human tumor cell lines and possesses antitumor properties in head and neck squamous cell carcinoma (HNSCC) through both p53-dependent and independent mechanisms, effectively restoring mutant p53 to a wild-type structure[1].[2].[3].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02433626 Ovarian Cancer ... More >> Fallopian Tube Cancer Endometrial Cancer Cervical Cancer Peritoneal Cancer Head and Neck Cancer HNSCC Less << Phase 1 Recruiting December 2018 United States, Illinois ... More >> Northwestern Memorial Hospital Recruiting Chicago, Illinois, United States Contact: Wilberto Nieves-Neira, MD    312-472-4684       Principal Investigator: Wilberto Nieves-Neira, MD          United States, Texas MD Anderson Cancer Centre Recruiting Houston, Texas, United States Contact: Shannon Westin, MD    713-794-4314       Principal Investigator: Shannon Westin, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.73mL

0.55mL

0.27mL

13.64mL

2.73mL

1.36mL

27.29mL

5.46mL

2.73mL

References

 

Historical Records

Categories